Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.
Geriatric Research, Education and Clinical Center, James J. Peters Veterans Affairs Medical Center, Bronx, New York, NY, 10468, USA.
Transl Psychiatry. 2020 Jun 9;10(1):183. doi: 10.1038/s41398-020-0859-x.
Major depressive disorder (MDD) is a leading cause of disability, and there is an urgent need for new therapeutics. Stress-mediated induction of pro-inflammation in the periphery contributes to depression-like behaviors both in humans and in experimental models. Inflammatory cytokine interleukin-6 (IL-6) has emerged as a potential therapeutic target. Our studies demonstrated that metabolism of flavanol rich cocoa preparation (FRP) led to the accumulation of select phenolic acids that may contribute to its anti-inflammatory activity. Using a repeated social defeat stress (RSDS) model of depression, we showed that oral administration of FRP attenuates susceptibility to RSDS-mediated depression, supporting the further development of FRP as a novel therapeutic for the treatment of stress disorders and anxiety in humans.
重度抑郁症(MDD)是导致残疾的主要原因,目前急需新的治疗方法。应激介导的外周炎症诱导与人类和实验模型中的抑郁样行为有关。炎症细胞因子白细胞介素-6(IL-6)已成为潜在的治疗靶点。我们的研究表明,富含黄烷醇的可可制剂(FRP)的代谢导致了某些酚酸的积累,这可能有助于其抗炎活性。使用重复社交挫败应激(RSDS)抑郁模型,我们表明 FRP 的口服给药可减轻 RSDS 介导的抑郁易感性,支持 FRP 作为治疗人类应激障碍和焦虑的新型治疗药物的进一步开发。